Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 10/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CFB | P00751 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11356202 | 0.80 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL10143149 | 0.77 | — | — | |
| SCHEMBL4401199 | 0.76 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL11125378 | 0.73 | — | — | |
| SCHEMBL24533674 | 0.72 | — | — | |
| SCHEMBL19533129 | 0.72 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL32681385 | 0.72 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL9558829 | 0.71 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL11125149 | 0.71 | SMN1; SMN2 (0.49) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 | |
| SCHEMBL1726232 | 0.69 | SMN1; SMN2 (0.43) | ADRA2AADRA2BADRA2CADRA1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306133-A1 | COMPOSITION FOR ADMINISTRATION OF DOUBLE-STRANDED OLIGONUCLEOTIDE STRUCTURES USING ULTRASONIC NEBULIZER FOR PREVENTION OR TREATMENT OF RESPIRATORY VIRAL INFECTION INCLUDING COVID-19, PULMONARY FIBROSIS CAUSED BY VIRAL INFECTION, OR RESPIRATORY DISEASES | Bioneer Corporation (KR) | 2024-01-17 | — | — | EP | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3888686-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE CONSTRUCT COMPRISING ANDROGEN RECEPTOR SPECIFIC SEQUENCE, AND COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING SAME | Bioneer Corporation (KR) | 2021-10-06 | — | — | EP | disclosed |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ADRA2A 3294/4885ADRA2B 2777/4885ADRA2C 2861/4885 |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ADRA2A 3294/4885ADRA2B 2777/4885ADRA2C 2861/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ADRA2A 2078/4885ADRA2B 1120/4885ADRA2C 1516/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | ADRA2A 2737/4885ADRA2B 1918/4885ADRA2C 2123/4885 |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ADRA2A 3294/4885ADRA2B 2777/4885ADRA2C 2861/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | ADRA2A 3894/4885ADRA2B 3503/4885ADRA2C 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.